VBL Therapeutics (Nasdaq: VBLT) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer

Our lead product candidate from our oncology program, VB-111, is a first-in class targeted anti-cancer biologic agent that is positioned to treat a wide range of solid tumors.

Safe and Convenient:

VB-111 is given through a simple IV infusion once every two months.  So far, VB-111 demonstrated efficacy signal in three Phase 2 studies – in rGBM, Ovarian cancer and Thyroid cancer.  VB-111 was safe and well-tolerated in over 200 cancer patients. It has potential for combination therapy with other drugs.


VB-111 utilizes genetically targeted therapy to destroy the newly formed, or angiogenic, blood vessels which nourish the tumor, leading to tumor starvation. In addition, VB-111 induces a local anti-tumor immune response.

Regulatory Status:

We have obtained fast track designation for VB-111 in the United States for prolongation of survival in patients with glioblastoma that has recurred following a treatment with standard chemotherapy and radiation. We have also received orphan drug designation in both the United States and Europe.

VBL Therapeutics’ pivotal Phase 3 GLOBE trial of VB-111 in rGBM is ongoing under a special protocol assessment granted by the FDA. Patient enrollment was completed in December 2016. The trial is conducted in the US, Canada and Israel . 

 For tumor-specific information, please click on the relevant indication.